Welcome to our dedicated page for Veradigm SEC filings (Ticker: MDRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Veradigm Inc. SEC filings document the company’s healthcare technology business, OTC-traded common stock and formal disclosures around financial reporting, governance and capital structure. Recent filings include Current Reports on Form 8-K covering leadership appointments, preliminary financial information, material agreements and amendments to the company’s stockholder rights plan.
The filing record also includes late-filing notices for annual reports, disclosures about financial reporting and internal-control matters, board-observer and stockholder-agreement arrangements, and the conclusion of an SEC investigation without a recommended enforcement action. These filings record Veradigm’s public-company status, common stock trading symbol MDRX, rights-plan mechanics and governance changes while the company works through delayed periodic reporting.
Veradigm Inc. entered into a Consulting Agreement with former interim CFO Leland Westerfield and Wilcox Capital LLC, effective June 1, 2026. The contractor will act as a Strategic Financial Advisor through March 31, 2027, helping with the CFO transition, SEC reporting and addressing material weaknesses in internal controls.
The company will pay a consulting fee of $45,937.50 per month for ten months, with the final two payments contingent on Westerfield signing and not revoking a general release of claims. Veradigm will also grant restricted stock units valued at $100,000 after it files its 2023 and 2024 Form 10-Ks, with those units vesting on March 31, 2027.
Veradigm Inc. files an annual report for the year ended December 31, 2024 that also provides expanded disclosures for 2023 in lieu of separate annual and quarterly reports. The company has undergone significant restatement work, internal control remediation and governance changes following earlier accounting issues.
Veradigm remains focused on healthcare technology and analytics across Provider, Payer and Life Science segments, emphasizing EHRs, revenue cycle management, payer analytics and real‑world data offerings. Recent developments include new board members, leadership changes, expanded equity incentive capacity, a new $100 million credit facility and full repayment of its 0.875% convertible notes due 2027, alongside ongoing remediation of material weaknesses and litigation related to prior periods.
MDRX: Two Seas Capital reports 8,943,265 shares (Common Stock) beneficially owned as of March 31, 2026. The Schedule 13G/A states that Two Seas Capital LP, Two Seas Capital GP LLC and Sina Toussi each may be deemed to have sole voting and dispositive power over 8,943,265 shares, representing 8.2% of the class.
The filing says the percent is calculated using 108,800,000 shares outstanding as of December 31, 2025, cited from an Exhibit to the issuer's prior Form 8-K. The Reporting Persons list their principal business address in Rye, New York.
Veradigm Inc. Schedule 13G/A: a group of Toronto-Dominion entities reports beneficial ownership of 8,814,833 shares of common stock, representing 8.1% of the class. The filing, signed May 15, 2026, attributes 1,314,733 shares to TD Securities (USA) LLC and 7,500,000 shares to Toronto Dominion Bank, with 100 shares held by TD Securities Inc. The statement is jointly filed under Rule 13d-1(k) and includes standard disclaimers of group ownership among the reporting entities.
Veradigm Inc. filing reports that Silver Point Capital and associated reporting persons beneficially own 3,559,758 shares, equal to 3.27% of common stock based on 108,800,000 shares outstanding as of December 31, 2025. This Amendment No. 3 is described as an "exit filing" and is jointly filed under a Joint Filing Agreement dated May 15, 2026.
The cover-page rows show shared voting and dispositive power for 3,559,758 shares held through Silver Point funds; the filing lists addresses for the issuer and the reporting persons and incorporates power-of-attorney exhibits.
Veradigm Inc. senior vice president and interim general counsel Eric L. Jacobson reported a routine tax-related share disposition. On May 10, 2026, 1,584 shares of common stock were withheld at $4.46 per share to cover withholding tax liabilities tied to vesting restricted stock units.
After this tax-withholding transaction, Jacobson directly owned 295,258 shares of Veradigm common stock. The filing reflects compensation-related withholding rather than an open-market purchase or sale.
Veradigm Inc. is notifying the SEC that it cannot timely file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 because it continues to address prior accounting misstatements and related internal control failures.
The company says its Board concluded certain historical consolidated financial statements for 2020 and 2021 and multiple interim periods should no longer be relied upon, and that the company delayed filing its 2022 Form 10-K until March 18, 2025 while investigating and remediating those matters. Veradigm lists a series of historical late filings it has not yet completed and notes receipt of a Nasdaq delisting notice and a Form 25 filing in April 2024. The company states it is working to complete the Historical Late Filings and the Q1 2026 Form 10-Q, but gives no definitive filing date.
Jacobson Eric L reported acquisition or exercise transactions in this Form 4 filing.
Veradigm Inc. reported that SVP Interim General Counsel Eric L. Jacobson received a grant of 75,000 shares of Common Stock in the form of Restricted Stock Units under the Veradigm Inc. 2024 Stock Incentive Plan. The award was granted on May 1, 2026 and vests in three equal annual installments on each of the first three anniversaries of the grant date.
Following this equity award, Jacobson directly holds 296,842 shares of Veradigm Common Stock. The grant represents compensation rather than an open-market share purchase, with no cash paid per share at grant.
Veradigm Inc. appointed Christian Greyenbuhl as its new Chief Financial Officer, principal financial officer and principal accounting officer, effective on the later of May 11, 2026 and the first business day after the company files its 2023 and 2024 Form 10-Ks, or as otherwise agreed. He replaces interim CFO Lee Westerfield, who is expected to move into a consulting role, and the company also plans the departure of Senior Vice President and General Counsel Tejal Vakharia.
Greyenbuhl’s compensation includes a $580,000 base salary, a $300,000 sign-on bonus, a target annual bonus equal to 75% of base salary, and an initial equity grant valued at $3,000,000 split between restricted stock units and performance stock units. Veradigm amended its 2024 Stock Incentive Plan to add 6,000,000 authorized shares, bringing the total available for equity awards to 17,000,000 shares.